Making the Cut: What You Need to Know About Biosimilars for Retinal Diseases

1-2 of 2

• 

  RestartResume

  The Era of Anti-VEGF Biosimilars: Navigating the Treatment Paradigm for Retinal Vascular Diseases

  RestartResume

  The Era of Anti-VEGF Biosimilars: Navigating the Treatment Paradigm for Retinal Vascular Diseases

  CME/CE

  The Era of Anti-VEGF Biosimilars: Navigating the Treatment Paradigm for Retinal Vascular Diseases

  Sophie J. Bakri, MD; Ankoor R. Shah, MD

  1.00 credit

  • 

    

    Sophie J. Bakri, MD

  • 

    

    Ankoor R. Shah, MD

  • 

    

    Sumit Sharma, MD

  • 

    

    Ashish Sharma, MD

  1.00 credit

• 

  RestartResume

  Making the Cut: What You Need to Know About Biosimilars for Retinal Diseases

  RestartResume

  Making the Cut: What You Need to Know About Biosimilars for Retinal Diseases

  CME/CE Broadcast Replay

  Making the Cut: What You Need to Know About Biosimilars for Retinal Diseases

  Sophie J. Bakri, MD; Ankoor R. Shah, MD

  1.50 credits

  • 

    

    Sophie J. Bakri, MD

  • 

    

    Ankoor R. Shah, MD

  • 

    

    Sumit Sharma, MD

  • 

    

    Ashish Sharma, MD

  1.50 credits